Transfer Factor as an Option for Managing the COVID-19 Pandemic
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články, přehledy
PubMed
33069187
DOI
10.14712/fb2020066030086
PII: file/5926/fb2020a0012.pdf
Knihovny.cz E-zdroje
- MeSH
- adjuvancia imunologická terapeutické užití MeSH
- Betacoronavirus MeSH
- COVID-19 MeSH
- koronavirové infekce imunologie terapie MeSH
- lidé MeSH
- pandemie MeSH
- SARS-CoV-2 MeSH
- transfer faktor terapeutické užití MeSH
- virová pneumonie imunologie terapie MeSH
- výzkumný projekt MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- adjuvancia imunologická MeSH
- transfer faktor MeSH
Covid-19 or SARS-CoV-2, a new RNA virus with high infectivity, and seemingly low mutability, which appeared in 2019 in the Wuhan province of China, has created a pandemic with dire consequences. At the end of May 2020, it became the first cause of mortality. As no treatment or vaccine may become available before many months, and because occurrence of similar pandemics is only a matter of time, arguments are presented here for testing the effect of transfer factor (TF), an immunomodulator devoid of toxicity, which has been extensively studied in the past for the treatment and prevention of viral infections.
HHV 6 Foundation Santa Barbara CA USA
Immunobiology Laboratory Faculté de Médicine Paris 6 France
Immunotherapy dept S Orsola Malpighi University Hospital Bologna Italy
Medical Oncology S Orsola Malpighi University Hospital Bologna Italy
Citace poskytuje Crossref.org
